Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...

Dec 17 () - Insmed said on Wednesday it had discontinued the development of its ​experimental anti-inflammatory drug to treat a ‌chronic sinus condition after it failed to show benefit in ‌a mid-stage ...

Angela Read thought she had a sinus infection, soon she discovered her condition was much more serious. She's grateful to the ...

The latest announcement is out from Insmed ( (INSM) ).

Insmed stock crumbled late Wednesday after the highly rated biotech company scrapped one of its brensocatib studies.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

Drug trials offer people with cancer hope and free medicine, but they also create incentives for doctors in private clinics ...

Insmed Inc (NASDAQ:INSM) stock tumbled 17.2% in after-hours trading Wednesday after the biopharmaceutical company announced its Phase 2b BiRCh study of brensocatib in patients with chronic ...